It will be pretty wild, as investors digest the $BioNTech SE(BNTX)$ earnings numbers compared with $Moderna, Inc.(MRNA)$ 's.
BNTX produced 40% more revenue in Q2, but only 7% in earnings. Considering each BNTX dose contains 30% of the MRNA's (30mg vs. 100mg), the significantly lower margin is a big surprise.
Plus the new data from Mayo Clinic show the low dosage jab produces much weaker result vs. MRNA's against the delta variant dominant cases, at 42% vs. 76%, that will continue to give MRNA an upper hand.
Congrats to all BNTX and MRNA longs! What a day!!
精彩评论